Psychedelic Microdosing and Drug Interactions | Neural Pharm Podcast
Exploring the science and data of microdosing, and briefing key drug interactions with the use of common used psychedelic therapies References: Cheung T. COMPASS Announces Positive Outcome of 25 mg COMP360 Psilocybin Therapy as Adjunct to SSRI Anti-depressant in Open-Label, Treatment-Resistant Depression Study. COMPASS Health. 13 Dec 2021 [press release]. Grinspoon P. The Popularity of Microdosing of Psychedelics: What Does the Science Say? Harvard Health. 19 Sept 2022. Gukasyan N, et al. Attenuation of Psilocybin Mushroom Effects During and After SSRI/SNRI Anti-depressant Use. Sage Journals. 2023 Jul; 37(7): 707-716 Malcolm B and Thomas K. Serotonin Toxicity of Serotonergic Psychedelics. Psychopharmacology. 2022;239: 1881-1891 Perez E, et al. The Psilocybin-Blunting Effects of SSRIs and Anti-depressants. Psychedelic Passage. 3 June 2022. Raison C, et al. Single Dose Psilocybin for Major Depressive Disorder. JAMA. 2023; 330(9): 843-853
You May Also Like

RDN Radio – Roma Daily News
Radio RDN - RomaDailyNews

BSD Now
JT Pennington

Las noticias de la SER
SER Podcast
The Podcast of the Lotus Eaters
lotuseaters.com

444 podcastek
444

Asmongold TV
Asmongold TV
Newshour
BBC World Service

The Diddy Diaries
Bobby Capucci

Siste nytt fra VG
VG
Lehto's Law
Lehto's Law
Community discussion